| pubmed-article:21413912 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21413912 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:21413912 | lifeskim:mentions | umls-concept:C0242643 | lld:lifeskim |
| pubmed-article:21413912 | lifeskim:mentions | umls-concept:C0085104 | lld:lifeskim |
| pubmed-article:21413912 | lifeskim:mentions | umls-concept:C1552617 | lld:lifeskim |
| pubmed-article:21413912 | lifeskim:mentions | umls-concept:C0175566 | lld:lifeskim |
| pubmed-article:21413912 | lifeskim:mentions | umls-concept:C0282443 | lld:lifeskim |
| pubmed-article:21413912 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:21413912 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:21413912 | pubmed:dateCreated | 2011-3-18 | lld:pubmed |
| pubmed-article:21413912 | pubmed:abstractText | INTRODUCTION: The ATP-binding cassette superfamily contains membrane transporter proteins that transport a wide range of diverse compounds across cellular membranes. The P-glycoprotein (P-gp) is an important member of this family and a multi-specific drug efflux transporter that plays a significant role in governing the bioavailability of many clinically active drugs. The inhibition of this efflux transporter by various P-gp inhibitors forms a distinctive approach in improving bioavailability and conquering drug resistance. Most P-gp inhibitors exhibit limitations associated with their safety and unwanted pharmacokinetic interactions, thereby restraining their clinical applicability. AREAS COVERED: This review explores the investigations on the feasibility and applicability of various classes of P-gp inhibitors as described in recent patents for enhanced drug delivery. EXPERT OPINION: Several candidates presently under development look promising as P-gp inhibitors, e.g., tariquidar and elacridar. Pharmaceutical excipients currently constitute the most promising class of P-gp inhibitors and are considered safe and pharmaceutically acceptable for use in formulations. In addition, lipid-based excipients and thiolated polymers play an active role in affecting P-gp-mediated transport not only by altering the membrane fluidity or ATPase activity but by down regulating P-gp expression. An additional overture such as the prodrug derivatization of P-gp substrates is a feasible approach to bypass P-gp-mediated efflux. | lld:pubmed |
| pubmed-article:21413912 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21413912 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21413912 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21413912 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21413912 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21413912 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21413912 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21413912 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21413912 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21413912 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21413912 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:21413912 | pubmed:issn | 1744-7674 | lld:pubmed |
| pubmed-article:21413912 | pubmed:author | pubmed-author:AhmadFarhan... | lld:pubmed |
| pubmed-article:21413912 | pubmed:author | pubmed-author:AhadAbdulA | lld:pubmed |
| pubmed-article:21413912 | pubmed:author | pubmed-author:JaggiManuM | lld:pubmed |
| pubmed-article:21413912 | pubmed:author | pubmed-author:AqilMohammedM | lld:pubmed |
| pubmed-article:21413912 | pubmed:author | pubmed-author:IqbalZeenatZ | lld:pubmed |
| pubmed-article:21413912 | pubmed:author | pubmed-author:TalegaonkarSu... | lld:pubmed |
| pubmed-article:21413912 | pubmed:author | pubmed-author:KharRoop... | lld:pubmed |
| pubmed-article:21413912 | pubmed:author | pubmed-author:AkhtarNaseemN | lld:pubmed |
| pubmed-article:21413912 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21413912 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:21413912 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21413912 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21413912 | pubmed:pagination | 561-76 | lld:pubmed |
| pubmed-article:21413912 | pubmed:meshHeading | pubmed-meshheading:21413912... | lld:pubmed |
| pubmed-article:21413912 | pubmed:meshHeading | pubmed-meshheading:21413912... | lld:pubmed |
| pubmed-article:21413912 | pubmed:meshHeading | pubmed-meshheading:21413912... | lld:pubmed |
| pubmed-article:21413912 | pubmed:meshHeading | pubmed-meshheading:21413912... | lld:pubmed |
| pubmed-article:21413912 | pubmed:meshHeading | pubmed-meshheading:21413912... | lld:pubmed |
| pubmed-article:21413912 | pubmed:meshHeading | pubmed-meshheading:21413912... | lld:pubmed |
| pubmed-article:21413912 | pubmed:meshHeading | pubmed-meshheading:21413912... | lld:pubmed |
| pubmed-article:21413912 | pubmed:meshHeading | pubmed-meshheading:21413912... | lld:pubmed |
| pubmed-article:21413912 | pubmed:meshHeading | pubmed-meshheading:21413912... | lld:pubmed |
| pubmed-article:21413912 | pubmed:meshHeading | pubmed-meshheading:21413912... | lld:pubmed |
| pubmed-article:21413912 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21413912 | pubmed:articleTitle | The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review. | lld:pubmed |
| pubmed-article:21413912 | pubmed:affiliation | Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard Hamdard University, New Delhi 110062, India. | lld:pubmed |
| pubmed-article:21413912 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21413912 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:21413912 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
